BioSpace News Archive

Roivant announced that it completed the redemption of its outstanding public warrants and private placement warrants that remained outstanding following 5:00 p.m. New York City Time on September 1, 2023 for a redemption price of $0.10 per Warrant.

Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced updated preclinical data supporting development of the Company’s WEE1 inhibitor candidate, ATRN-1051, for the treatment of ovarian cancer.

BioVie Inc. today announced that preliminary baseline data from its multicenter, randomized, placebo-controlled Phase 3 study (NCT04669028) of NE3107 in patients with mild to moderate Alzheimer’s Disease.

eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced the addition of Caroline Loewy to its Board of Directors and her election as Chair of the Board’s Audit Committee.

Evofem Biosciences, Inc. announced it has successfully negotiated and entered into a fourth amendment to its Securities Purchase and Security Agreement dated April 2020, as amended, with a U.S.-based, healthcare-focused institutional investor, under which the Investor purchased $25 million of convertible senior secured promissory notes from Evofem.

Limaca Medical (“Limaca”) announced today that its Precision GI™ Endoscopic Ultrasound (EUS) Biopsy Device received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”). This follows Limaca’s receipt of FDA Breakthrough Device Designation for its Precision GI™.

Medivir AB announced that Medivir’s partner Tango Therapeutics has received FDA clearance on its Investigational New Drug application for TNG348.

Visgenx, Inc. announced that the Company presented a poster on its synthetic AAV platform at the Cell and Gene Therapy: Advancing Next Generation Therapies, West Coast Symposium on September 7th in Brisbane, California.

Heartseed announced that the case reports of two patients in the Phase 1/2 clinical trial of HS-001 in combination with coronary artery bypass grafting surgery for advanced heart failure, was presented by the investigator at the 71st Annual Meeting of the Japanese College of Cardiology on September 9, 2023.

Oculis Holding AG, a global biopharmaceutical company purposefully driven to save sight and improve eye care, announced the appointment of global commercial executive with extensive ophthalmology experience, Rebecca Weil, to the role of Chief Commercial Officer.